Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jazz Pharmaceuticals PLC

120.02
+2.842.42%
Volume:271.77K
Turnover:32.48M
Market Cap:7.29B
PE:13.88
High:120.23
Open:118.82
Low:118.75
Close:117.18
Loading ...

Jazz Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
10 Mar

Jazz Pharmaceuticals Plc : H.c. Wainwright Raises Target Price to $217 From $200

THOMSON REUTERS
·
10 Mar

LTRN: M&A Illuminates GBM Value

Zacks Small Cap Research
·
10 Mar

Why Chimerix, Inc. (CMRX) Soared Last Week

Insider Monkey
·
10 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Mobileye, Visionary Holdings, Wolfspeed

Reuters
·
08 Mar

UBS Upgrades Jazz Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $179 From $145

MT Newswires Live
·
08 Mar

Corcept Shares Rise More Than 55% in 6 Months: Here's Why

Zacks
·
07 Mar

BUZZ-Jazz Pharma climbs after Morgan Stanley raises PT

Reuters
·
07 Mar

Jazz Pharmaceuticals Raised to Buy From Neutral by UBS

Dow Jones
·
07 Mar

Positive Outlook for Jazz Pharmaceuticals: Buy Rating Backed by Strong Growth Prospects and Strategic Focus

TIPRANKS
·
07 Mar

Jazz Pharmaceuticals upgraded to Buy from Neutral at UBS

TIPRANKS
·
07 Mar

The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals

Zacks
·
07 Mar

Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More

Zacks
·
07 Mar

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251

Benzinga
·
07 Mar

Update: Truist Raises PT on Jazz Pharmaceuticals to $230 From $220 on Heels of Announced Purchase of Chimerix, Keeps Buy Rating

MT Newswires Live
·
07 Mar

AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals

Zacks
·
06 Mar

Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio

Zacks
·
06 Mar

Jazz Pharmaceuticals price target raised to $230 from $220 at Truist

TIPRANKS
·
06 Mar

Beat Market Volatility With 4 Low-Beta Stocks: PGR, PSO, TXO & JAZZ

Zacks
·
06 Mar

Truist Raises Price Target on Jazz Pharmaceuticals to $230 From $220, Keeps Buy Rating

MT Newswires Live
·
06 Mar